CAND1 mediates CUL7-dependent HER2 protein stability to drive breast cancer progression
Open Access
- 27 November 2025
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research
- Vol. 27 (1) , 211
Abstract
HER2-positive breast cancer is a prevalent pathological subtype of breast cancer. Resistance to anti-HER2 targeted therapies remains a significant challengKeywords
Funding Information
- National Natural Science Foundation of China (82373327, 8240111911, 82403028, 82373327, 8240111911, 82403028)
- Guangdong Basic and Applied Basic Research Foundation (2021A1515110868)
- Science and Technology Program of Guangzhou (2023A03J0427)
- Innovation team of general Universities in Guangdong Province (2022KCXTD021)
This publication has 40 references indexed in Scilit:
- Practical implications of gene-expression-based assays for breast oncologistsNature Reviews Clinical Oncology, 2011
- NEDD8 Pathways in Cancer, Sine Quibus NonCancer Cell, 2011
- Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancerCritical Reviews in Oncology/Hematology, 2010
- Cullin neddylation and substrate‐adaptors counteract SCF inhibition by the CAND1‐like protein Lag2 in Saccharomyces cerevisiaeThe EMBO Journal, 2009
- The neuregulin-I/ErbB signaling system in development and disease.2007
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Structure of the Cand1-Cul1-Roc1 Complex Reveals Regulatory Mechanisms for the Assembly of the Multisubunit Cullin-Dependent Ubiquitin LigasesCell, 2004
- The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of TherapyThe Oncologist, 2003
- Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/NeuProceedings of the National Academy of Sciences, 2002
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989